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In a recent issue of Nature Medicine, Ryan et al. (2010) uncover genetic modifiers of G-CSF responses by
hematopoietic progenitors. The authors document a negative role of EGFR signaling and, provided an anal-
ogous pathway functions in humans, propose a potential new angle to promote clinical blood stem cell mobi-
lization.In postnatal life, virtually all hematopoietic
stem cells (HSCs) and their developing
progeny are confined to the bone marrow
(BM) in which complex customizedmicro-
environments or ‘‘niches’’ are tailored to
support their survival and specialized
functions (Garrett and Emerson, 2009).
In contrast to these ‘‘home bodies,’’
a small fraction of stem/progenitor cells
exhibit a migratory lifestyle and circulates
through blood and other tissues. Although
some specific phenotypic traits have
been identified that characterize this
population, why and where they escape
the BM is still debated. Beyond the basic
mechanistic debate surrounding the
mobilization of primitive blood cells,
a variety of empiric methods have been
developed over that last four decades
(Papayannopoulou and Scadden, 2008)
that precipitate an enforced migration of
these cells into the peripheral circulation
and that have dramatically changed clin-
ical practice. One of the approaches, the
use of G-CSF, has dominated the field,
and even before mechanistic details
were delineated, it became the preferred
source for obtaining hematopoietic stem
cell grafts, both allogeneic and autolo-
gous (Leung and Kwong, 2010). However,
during this period, a wealth of published
observations has revealed that the
response to G-CSF is highly variable and
that a subset of normal donors fails to
achieve target doses for transplantation
(4 3 10E6 CD34+/Kg body weight after
two aphereses). This deficiency has moti-
vated a search for alternative means to
enhance mobilization, and the results
have provided insight into the nature of
retention mechanisms in BM, even before
the specific role played by G-CSF was
known (Broxmeyer et al., 2005). In addi-
tion, the multitude of substances andconditions leading to mobilization has
provided hints as to the involvement of
other, unsuspected pathways important
in stem cell retention and highlights the
existence of a delicate equilibrium be-
tween marrow retention and egress. The
recent study published by Ryan et al.
(2010) uses a genetic approach to provide
a new twist on our understanding of the
mechanisms at work during mobilization.
It has been known for some time that
similar differences in mobilization, both
at baseline and after G-CSF, are observed
in patients and among different murine
strains. For example, DBA mice mobilize
10-fold better than C57Bl/6 mice. Using
a laborious genetic approach, Ryan and
colleagues partially unraveled the genetic
basis for this difference (Ryan et al., 2010).
The authors created a hybrid mouse
strain, called strain 1804, that combines
a C57Bl/6 background with homologous
replacement of a 5 MBp fragment of
chromosome 11 from a DBA mouse.
This hybrid mouse responded to G-CSF
with a 3-fold higher efficiency than did
animals from the parental C57Bl/6 strain.
When WT recipients were engrafted with
BM from strain 1804, the high mobilizing
phenotype was recapitulated when the
reconstituted mice were challenged with
G-CSF, indicating that hematopoietic
cell-intrinsic differences were responsible
for the strain-specific difference. Of the 12
genes located on the critical fragment of
chromosome 11, the expression of one
gene of particular interest, epidermal
growth factor receptor, EGFR, was
elevated in a population of HSPCs from
C57Bl/6 relative to strain 1804 mice. The
genetic basis for the different expression
levels was not immediately apparent, in
that no polymorphisms were identified in
the EGFR gene or in surrounding putativeCell Stem Cell 7,regulatory regions. Yet, steady-state
EGFR expression on HSPCs was nega-
tively associated with the ability to res-
pond to G-CSF. Moreover, in all strains,
in vivo treatment with G-CSF reduced
EGFR message in HSPC-enriched popu-
lations to about 40% of steady-state
levels. Taken together, these data sug-
gested a functional association between
EGFR downregulation and HSPC mobili-
zation, which led the authors to examine
the role of EGFR signaling. Indeed, phar-
macologic and genetic enhancers and
inhibitors of EGFR signaling modified
responsiveness of mice to GCSF. Specif-
ically, activation of EGFR with EGF atten-
uatedmobilization, while the EGFR antag-
onist Erlotinib enhanced mobilization of
progenitor cells by two-fold and had an
even greater impact on the mobilization
of more primitive subsets.
As a functionally relevant downstream
target of EGFR, the authors identified
thesmallRhoGTPaseCdc42asanegative
regulator of mobilization. Cdc42-deficient
mice had a similar mobilization phenotype
asanEGFR-signaling-deficient (waved2/+)
mouse strain, or mice treated with Erloti-
nib, in that all of these mice were highly
responsive to G-CSF. Surprisingly,
Cdc42 was inactive during steady state
(when EGFR expression on HSPCs was
relatively high) but activated in response
to G-CSF (when EGFR expression was
low), but only in C57Bl/6 mice, consistent
with the model that it functions down-
stream of the effects of G-CSF. However,
no Cdc42 activation was observed in the
constitutively EGFR-low hybrid strain
1804, even after exposure to G-CSF. The
molecular basis of this response pattern
is not clear. Does G-CSF activate EGFR
ligands in marrow stroma at the same
time that it reduces EGFR expression, orNovember 5, 2010 ª2010 Elsevier Inc. 547
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Previewscould it facilitate EGFR cross-signaling,
perhaps?
Clearly, several issues warrant further
exploration. For instance, even during
steady-state conditions, DBAmice exhibit
much higher circulating progenitor cell
numbers than C57Bl/6 mice, while in the
hybrid mice, steady-state hematopoiesis
is normal. This observation indicates that
there are additional modifiers of steady-
state hematopoiesis that distinguish
C57Bl/6 from DBA mice. Whether EGFR
blockade influences HSPC proliferation,
thus enhancingmobilization by increasing
the pool ofmobilizable cells, or has amore
direct effect on BM retention by cooperat-
ing with other pathways remains open to
question. An ample body of data from
cancer cell lines suggest a remarkable
degree of overlap among the signaling
pathways downstream of CXCR4 and
EGFR, involving PKCzeta (Wu et al.,
2010), and crosstalk as well as cross-acti-
vation of EGFR and CXCR4 (Mosadegh
et al., 2008; Pattarozzi et al., 2008; Guo
et al., 2007; Woerner et al., 2005). Of
note, there is a remarkable contrast
between the effects of EGFR signaling on
normal hematopoietic cells and cancer
cells, in that EGFR signals are associated
with increased proliferation and motility
in cancer cells. From this perspective,
onemight predict that treatment of cancer
patients with a combination of G-CSF and
Erlotinib could serve to enhance mobiliza-
tion and also to suppress residual cancer
cells at the same time. Thus, there are548 Cell Stem Cell 7, November 5, 2010 ª20data that support divergent views of
EGFR-dependent effects on normal
versus cancer cells, and the genetic
approach taken by Ryan et al. offers
a good template for use in the formulation
of new hypotheses.
Are there any clinical implications of
these data? Given that EGFR antagonists
such as Erlotinib had no effect on mobili-
zation when used in isolation, treatment
with this class of drugs is unlikely to
benefit patients or donors intolerant to
G-CSF. However, assuming that their
data can be confirmed in humans, Ryan
and colleagues propose that Erlotinib
might serve as a useful adjuvant for
mobilization of poorly responsive alloge-
neic donors or autologous patients
cotreated with chemotherapy and
G-CSF. This strategy has already been
used to combine G-CSF with the CXCR4
antagonist AMD3100, which has been
approved to support mobilization in such
patients. For allogeneic donors, it
remains to be seenwhether a combination
therapy with EGFR antagonists will
achieve a relevant clinical benefit for
poor mobilizers, given than only a 2-fold
increase was observed in mice. For autol-
ogous patients, the cumulative marrow
toxicity of prior chemotherapy may over-
shadow the enhancing effects of genetic
modifiers. Furthermore, there are addi-
tional caveats that require clarification
before this approach could be considered
for use in cancer patients. For example,
will Erlotinib be associated with negative10 Elsevier Inc.effects on residual cancer cells, which
would be welcomed, or could this
oncogenic population also be mobilized
by the new regimen? The latter case
would be an obvious detriment during
graft collection and therefore must be
approached with caution.
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